04.14.21 -- Advice For Aspiring Biopharma CEOs : vimarsana.c

04.14.21 -- Advice For Aspiring Biopharma CEOs


04.14.21 -- Advice For Aspiring Biopharma CEOs
 
 
State-of-the-art continuous manufacturing technologies are being developed and implemented to manufacture a wide variety of products. Several vendors offer development-scale to commercial-scale continuous downstream chromatography systems. When adopting continuous technology, it is critical to demonstrate that continuous downstream processes are comparable to batch-mode downstream processes and provide the supporting comparability data for technical and business decisions.
Access the case study to learn more.
Featured Articles
 
In my experience, the most effective leaders are intentional about everything they do: how they speak, how they listen, the everyday conduct of their lives.
Video
 
Michael McCullar, Ph.D., CEO of OnQuality Pharmaceuticals, kicks off this executive virtual roundtable segment by discussing some of the challenges around diversity and inclusion (D&I) during M&A transactions between U.S. startups and non-U.S.-based global biopharmaceutical companies. Additional insight on D&I is provided by Pen Lu, M.D., Ph.D., chief medical officer of Pharvaris, and Edith Perez, M.D., chief medical officer at Bolt Biotherapeutics.

Related Keywords

Edith Perez , Michael Mccullar , Onquality Pharmaceuticals , எடித் பெரெஸ் , மைக்கேல் ம்க்குள்ளார் ,

© 2025 Vimarsana